（５月３１日付 ヘプタレス社 HP Latest Newsより抜粋）
Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist
New findings highlight complexity of receptor interactions and provide crucial insights for development of peptide and small molecule therapeutics – research published in Nature
London, UK, 31 May 2017 – Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), has published the first high-resolution X-ray crystal structure of the full-length glucagon-like peptide-1 (GLP-1) receptor bound to a peptide agonist.
（５月３１日付 ヘプタレス社 HP Latest Newsより抜粋）
Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist
New findings highlight complexity of receptor interactions and provide crucial insights for development of peptide and small molecule therapeutics – research published in Nature
London, UK, 31 May 2017 – Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), has published the first high-resolution X-ray crystal structure of the full-length glucagon-like peptide-1 (GLP-1) receptor bound to a peptide agonist.
・・・
そーせいの中長期ファンダメンタルズに変化なし。
今後も、悪しき空売り機関の餌食とならぬよう、
ゆったりゆっくり着実に現物長期で。。
創薬力＆成長性に対する評価、注目度は青天井！！
グローバルバイオ企業への序章〜次なる大飛躍、
日本版ギリアドへ。
頑張れ、そーせい！！